{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.15","upperLimit":"10.00","value":"4.00"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"10.00","value":"5.90"},{"groupId":"OG002","lowerLimit":"0.50","upperLimit":"10.00","value":"3.03"},{"groupId":"OG003","lowerLimit":"1.10","upperLimit":"10.00","value":"4.44"},{"groupId":"OG004","lowerLimit":"0.50","upperLimit":"2.00","value":"1.00"},{"groupId":"OG005","lowerLimit":"0.50","upperLimit":"6.05","value":"3.00"},{"groupId":"OG006","lowerLimit":"0.42","upperLimit":"10.00","value":"5.85"},{"groupId":"OG007","lowerLimit":"0.35","upperLimit":"10.00","value":"3.10"},{"groupId":"OG008","lowerLimit":"1.00","upperLimit":"10.02","value":"6.50"},{"groupId":"OG009","lowerLimit":"0.50","upperLimit":"8.00","value":"1.53"},{"groupId":"OG010","lowerLimit":"3.00","upperLimit":"10.00","value":"7.08"},{"groupId":"OG011","lowerLimit":"0.50","upperLimit":"8.07","value":"4.00"},{"groupId":"OG012","lowerLimit":"2.87","upperLimit":"2.87","value":"2.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"81"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"1"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"4.00","value":"0.98"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"10.00","value":"3.00"},{"groupId":"OG002","lowerLimit":"2.00","upperLimit":"8.08","value":"6.17"},{"groupId":"OG003","lowerLimit":"0.97","upperLimit":"6.00","value":"6.00"},{"groupId":"OG004","lowerLimit":"0.50","upperLimit":"9.97","value":"2.00"},{"groupId":"OG005","lowerLimit":"0.48","upperLimit":"10.08","value":"2.95"},{"groupId":"OG006","lowerLimit":"2.00","upperLimit":"10.02","value":"6.96"},{"groupId":"OG007","lowerLimit":"0.30","upperLimit":"10.32","value":"3.65"},{"groupId":"OG008","lowerLimit":"0.97","upperLimit":"10.03","value":"4.00"},{"groupId":"OG009","lowerLimit":"1.00","upperLimit":"7.93","value":"5.95"},{"groupId":"OG010","lowerLimit":"0.98","upperLimit":"9.87","value":"7.92"},{"groupId":"OG011","lowerLimit":"1.00","upperLimit":"9.83","value":"6.00"},{"groupId":"OG012","lowerLimit":"0.53","upperLimit":"4.00","value":"2.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"102"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"}],"units":"Participants"}],"title":"Cycle 2, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"102"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"}],"units":"Participants"}],"description":"Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL.","dispersionType":"Full Range","groups":[{"description":"Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Enasidenib 30 mg BID"},{"description":"Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG001","title":"Enasidenib 50 mg BID"},{"description":"Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG002","title":"Enasidenib 75 mg BID"},{"description":"Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity","id":"OG003","title":"Enasidenib 100 mg BID"},{"description":"Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG004","title":"Enasidenib 150 mg BID"},{"description":"Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG005","title":"Enasidenib 50 mg QD"},{"description":"Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG006","title":"Phase 1 Dose Escalation: Enasidenib 75 mg QD"},{"description":"Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG007","title":"Phase 1 Dose Escalation: Enasidenib 100 mg QD"},{"description":"Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG008","title":"Phase 1 Dose Escalation: Enasidenib 150 mg QD"},{"description":"Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG009","title":"Phase 1 Dose Escalation: Enasidenib 200 mg QD"},{"description":"Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG010","title":"Phase 1 Dose Escalation: Enasidenib 300 mg QD"},{"description":"Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG011","title":"Phase 1 Dose Escalation: Enasidenib 450 mg QD"},{"description":"Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG012","title":"Phase 1 Dose Escalation: Enasidenib 650 mg QD"}],"paramType":"MEDIAN","populationDescription":"Participants who received enasidenib on Cycle 1, Day 15 or Cycle 2, Day 1 with sufficient data to determine PD parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis. Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.","title":"Phase 1: Time of Minimum Observed Concentration Over 10 Hours Postdose (Tmin) of 2-HG After Multiple Oral Doses of Enasidenib","type":"SECONDARY","unitOfMeasure":"hours"}